• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    579.86 -1.88 (-0.32%)
    Streaming Delayed Price Updated: 11:37 AM EDT, May 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about United Therapeutics Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    News headline image
    5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
    United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attribu... 
    Via StockStory
    Topics Earnings
    News headline image
    United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook
    Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to... 
    Via StockStory
    United Therapeutics (NASDAQ:UTHR) Shares Dip After Q1 2026 Earnings Miss ↗
    Via Chartmill
    United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗
    Via Chartmill
    News headline image
    UTHR Q1 2026 Earnings Transcript ↗
    UTHR Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
    Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to $781.... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Reports First Quarter 2026 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
    From MannKind
    Via GlobeNewswire
    News headline image
    United Therapeutics (UTHR) Q1 Earnings Report Preview: What To Look For
    Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before market hours. Here’s what to look for. United Therape... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    The eVTOL Era is Beginning With Uber and Joby Aviation: What Investors Need to Know ↗
    The eVTOL market is preparing for takeoff in 2026, but which stocks will win out over the long term? 
    Via The Motley Fool
    News headline image
    United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    UTHR Q4 2025 Earnings Transcript ↗
    UTHR Q4 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Reasons Investors Love United Therapeutics (UTHR)
    Since April 2021, the S&P 500 has delivered a total return of 68.6%. But one standout stock has more than doubled the market - over the past five years, Unit... 
    Via StockStory
    Topics Stocks
    News headline image
    United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Market-Beating Stocks for Long-Term Investors
    Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
    Via StockStory
    Topics Energy
    News headline image
    United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
    In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso... 
    Via MarketMinute
    Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market ↗
    Via Chartmill
    Topics Economy
    News headline image
    Why United Therapeutics (UTHR) Stock Is Up Today
    What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 12.7% in the afternoon session after the company announced its TETON-... 
    Via StockStory
    Traders are paying attention to the gapping stocks in Monday's session. ↗
    Via Chartmill
    News headline image
    United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
    Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
    Via StockStory
    News headline image
    Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers
    Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid
    Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
    Via StockStory
    News headline image
    1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm
    A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
    Via StockStory
    Topics Firearms
    News headline image
    This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
    Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
    Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide. 
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.